Scinai Immunotherapeutics Announces Growth and Extended Financial Strategy Following New Financing

Scinai Immunotherapeutics Ltd., a biopharmaceutical firm known for its innovative therapies, has recently conveyed an important update to its shareholders through a letter from CEO Amir Reichman. This communication highlights the substantial progress made by the company in terms of its Contract Development and Manufacturing Organization (CDMO) capabilities, bolstered liquidity, and an extended financial runway.

In an exciting move, Scinai established a CDMO agreement with a Nasdaq-listed biopharmaceutical partner, which encompasses committed service fees totaling around $5.1 million. This venture signifies not only a deepening of an existing relationship but also a notable increase in the value of committed customer orders, climbing to approximately $8.1 million compared to just $1.9 million at the end of 2025—an impressive growth of over 300%.

These contracts indicate a growing trust in Scinai’s automated manufacturing processes and overall operational excellence, especially in light of competitive proposals from significantly larger players in the CDMO space. The company’s unique ability to tailor development plans according to the specific needs of its customers has played a crucial role in this positive shift.

The forthcoming phases of the CDMO agreement will see a variety of activities converge, including clinical supply, stability testing, and manufacturing readiness. These initiatives are not just isolated occurrences; they reflect an integrative approach to medicine development and production, all designed around the demands of regulatory requirements and market need. With anticipated activities well into 2028, Scinai's structured approach could likely yield over $10 million in combined potential services.

Moreover, the financial robustness demonstrated through last week's completion of financing is a critical factor in Scinai's operational strategy. The company raised approximately $1.67 million via a Standby Equity Purchase Agreement, alongside $4 million through private placement, netting around $3.6 million after necessary transaction expenses. Such a financial influx enhances the company's capacity to fulfill their commitments and explore further opportunities within the competitive landscape.

The prolonged operational runway—estimated to extend to late 2027 and possibly into the third quarter of 2028—offers Scinai a vital advantage. This timeframe allows them to deliver contracted work effectively, improve facility efficiency, and attract additional business, thus contributing positively to cash flow. This operational buffer also provides shareholders with the confidence that the company is poised for sustainable growth.

The CEO stresses the necessity of effective execution. In addition to managing finances prudently, Scinai is dedicated to not just sustaining quality but excelling in operational standards. This commitment will invariably lead to better utilization of facilities and human resources, aligning closely with customer expectations.

Furthermore, expanding the customer base has emerged as a top priority for Scinai, with plans to tap into markets across the United States and Europe. By focusing on projects that align with their capabilities and that boast credible funding, they hope to bolster their portfolio while lessening dependence on individual contracts.

In conjunction with the CDMO ambitions, Scinai's therapeutic development strategy remains steadfast in focusing on the NanoAb platform and collaborations with esteemed institutions like the Max Planck Society and University Medical Center Göttingen. This dual-focus aims to merge financial efficiency while propelling their innovative therapies to market.

In conclusion, Scinai Immunotherapeutics is poised for significant advancements, with a clear roadmap for leveraging both its CDMO services and therapeutic development strategies to enhance shareholder value. The commitment to operational excellence and quality customer outcomes will undoubtedly play a crucial role in their success. Continued updates on their progress and achievements are anticipated, reflecting the company's dedication to transparency and performance enhancement.

For further inquiries or detailed discussions regarding committed customer orders, financial strategy, or operational innovations, stakeholders are encouraged to reach out to Scinai’s investor relations team.